廣告
香港股市 將收市，收市時間：4 小時 22 分鐘

  • 恒指

    17,601.95
    +317.41 (+1.84%)
     

  • 國指

    6,255.59
    +135.22 (+2.21%)
     

  • 上證綜指

    3,076.92
    +24.02 (+0.79%)
     

  • 滬深300

    3,566.74
    +36.46 (+1.03%)
     

  • 美元

    7.8298
    +0.0020 (+0.03%)
     

  • 人民幣

    0.9250
    +0.0007 (+0.08%)
     

  • 道指

    38,085.80
    -375.12 (-0.98%)
     

  • 標普 500

    5,048.42
    -23.21 (-0.46%)
     

  • 納指

    15,611.76
    -100.99 (-0.64%)
     

  • 日圓

    0.0499
    -0.0001 (-0.30%)
     

  • 歐元

    8.3933
    -0.0049 (-0.06%)
     

  • 英鎊

    9.7820
    -0.0100 (-0.10%)
     

  • 紐約期油

    83.79
    +0.22 (+0.26%)
     

  • 金價

    2,345.10
    +2.60 (+0.11%)
     

  • Bitcoin

    64,412.97
    +46.73 (+0.07%)
     

  • CMC Crypto 200

    1,389.70
    +7.12 (+0.52%)
     

Roche Introduces Test To Detect Contagious XBB.1.5 Omicron Sub-Variant

Anusuya Lahiri
·1 分鐘文章

  • Roche Holding Ltd (OTC: RHHBF) (OTC: RHHBY) and its subsidiary TIB Molbiol have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5.

  • The XBB.1.5 Omicron sub-variant is prevalent in the U.S. and quickly spreads to other countries.

  • Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment strategies.

  • "Roche continues to develop timely diagnostic innovations related to COVID-19 by providing valuable insights - helping scientists and physicians understand this new strain, how it differs from other variants, and the impact it may have on public health," said Matt Sause, CEO of Roche Diagnostics.

  • The research-use-only test, VirSNiP SARS-CoV-2 Spike F486P, adds to the broad suite of COVID-19 test kits developed by Roche and TIB Molbiol.

  • Roche's Q3 FY22 sales reached CHF14.74 billion, down 6% Y/Y due to lower sales from COVID-19 treatments and diagnostics.

  • "The third quarter of 2022 was particularly challenging due to base effects, as the demand for COVID-19 medicines and tests was exceptionally high in the same quarter of 2021," the company said.

  • "Despite an increasing incidence rate for COVID-19, actually, we don't see an increase in the demand for COVID-19-related products," CEO Severin Schwan said.

  • Price Action: RHHBY shares closed at $40.05 on Wednesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article originally appeared on Benzinga.com

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.